

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: DAVID LUKTON Examiner #: 71263 Date: 06-18-03
Art Unit: 1653 Phone Number 308-3213 Serial Number: 09-776466
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

Mail Box: 9B01; Ex Rm: 9B05
If more than one search is submitted, please prioritize searches in order of need.

*** Title: Glycopeptide derivatives *
Plea _____
Inch _____
utili _____
know _____
Titl _____
Inv _____
Ear _____

Applicants: Christensen, Burton G.; Judice, J. Kevin; Mu, YongQi
Earliest Priority Date: 2/4/00

Applicants are claiming the structures on the attached sheet.

- *Fe
app
- R2 = anything
 - R3 = anything
 - R4 = anything
 - R5 = anything
 - R6 = anything
 - R7 = anything
 - R8 = anything
 - R9 = anything
 - R10 = anything
 - R11 = anything
 - R12 = anything
 - R13 = anything
 - R15 = anything
 - R16 = hydrogen
 - R17 = anything

- X1 = hydrogen or chlorine
- X2 = hydrogen or chlorine
- X3 = hydrogen or chlorine

Point of Contact
P. Sheppard
telephone number: (703) 308-4499

n = an integer of 0, 1, or 2

W = anything but cannot be hydrogen or hydroxyl

STAFF USE ONLY

Type of Search	Vendors and cost where applicable
NA Sequence (#) _____	STN _____
AA Sequence (#) _____	Dialog _____
Structure (#) _____	Questel/Orbit _____
Bibliographic _____	Dr. Link _____
Litigation _____	Lexis/Nexis _____
Fulltext _____	Sequence Systems _____
Patent Family _____	WWW/Internet _____
Other _____	Other (specify) _____

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: 6/18/03
Searcher Prep & Review Time: _____
Clerical Prep Time: _____
Online Time: _____

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 18:11:24 ON 18 JUN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jun 2003 VOL 138 ISS 25
 FILE LAST UPDATED: 17 Jun 2003 (20030617/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
 =>

=> d stat que l12
 L1 STR




NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE

L3 STR



VAR G1=CH3/44

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 45

STEREO ATTRIBUTES: NONE

L7 STR



Page 1-A



Page 2-A

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 59

STEREO ATTRIBUTES: NONE

L10 2863 SEA FILE=REGISTRY SSS FUL L1

L11 308 SEA FILE=REGISTRY SUB=L10 SSS FUL L7 NOT L3

L12 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L11

=>

=>

=> d ibib abs hitrn l12 1-9

L12 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:585482 HCAPLUS

DOCUMENT NUMBER: 138:180210

TITLE: Structural requirements for VanA activity of
vancomycin analogues

AUTHOR(S): Chen, Zhong; Eggert, Ulrike S.; Dong, Steven D.; Shaw,

CORPORATE SOURCE: Simon J.; Sun, Binyuan; LaTour, John V.; Kahne, Daniel
 Department of Chemistry, Princeton University,
 Princeton, NJ, 08544, USA
 SOURCE: Tetrahedron (2002), 58(32), 6585-6594
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB We have prepd. several sets of glycopeptide analogs in order to probe the mol. basis for the activity of derivs. that overcome vanA resistance. The results described in this paper provide compelling evidence that good vanA activity is due to a mechanism of action that does not involve peptide binding. Hypothesizing that this mechanism of action involves an interaction of the disaccharide portion of vancomycin analogs with bacterial transglycosylases, we have prepd. a compd. in which the vancomycin aglycon is coupled to a known transglycosylase inhibitor that is structurally unrelated to the disaccharides that have been previously investigated. The activity of this compd. is excellent. This work provides a clear prescription for the design of better glycopeptide analogs.

IT 256350-01-3 322012-74-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (prepn. and structure-activity relationship of vancomycin analogs and antibacterial resistance)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:175755 HCAPLUS

DOCUMENT NUMBER: 137:345587

TITLE: Antibacterial activity of G6-quaternary ammonium

derivatives of a lipophilic vancomycin analogue
 AUTHOR(S): Blizzard, Timothy A.; Kim, Ronald M.; Morgan, Jerry D.; Chang, Jiang; Kohler, Joyce; Kilburn, Ruth; Chapman, Kevin; Hammond, Milton L.

CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002),
 12(6), 849-852

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of G6-amino derivs. of a lipophilic vancomycin analog was prepd. Antibacterial activity of the analogs was inversely proportional to the degree of substitution of the G6-nitrogen. The fully substituted (quaternary) analogs were essentially inactive against vanA phenotype VREF strains but retained substantial activity against other bacteria, a profile reminiscent of teicoplanin.

IT 308366-82-7P 474433-05-1P 474433-06-2P

474433-07-3P 474433-08-4P 474433-09-5P

474433-10-8P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(structure-activity relationship studies and antibacterial activity of G6-quaternary ammonium derivs. of a lipophilic vancomycin analog)

IT 474432-97-8

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structure-activity relationship studies and antibacterial activity of G6-quaternary ammonium derivs. of a lipophilic vancomycin analog)

IT 256351-48-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (structure-activity relationship studies and antibacterial activity of
 G6-quaternary ammonium derivs. of a lipophilic vancomycin analog)
 IT 474432-98-9P 474432-99-0P 474433-00-6P
 474433-01-7P 474433-02-8P 474433-03-9P
 474433-04-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (structure-activity relationship studies and antibacterial activity of
 G6-quaternary ammonium derivs. of a lipophilic vancomycin analog)
 REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:798249 HCAPLUS
 DOCUMENT NUMBER: 135:331682
 TITLE: Preparation of glycopeptide vancomycin analogs as
 antibacterial agents
 INVENTOR(S): Kim, Ronald M.; Tata, James R.; Chapman, Kevin
 PATENT ASSIGNEE(S): Merck + Co., Inc., USA
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081373	A2	20011101	WO 2001-US13042	20010424
WO 2001081373	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 2002045574 A1 20020418 US 2001-840927 20010425 PRIORITY APPLN. INFO.: US 2000-199359P P 20000425 OTHER SOURCE(S): MARPAT 135:331682 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Glycopeptide Vancomycin analogs I wherein R₁ is XR; X is absent or XR is
 NH=NRR, SO₂R, So₂NRR, CO₂R, CONRR, COR, R₂ is NRR, SR, NHC(=NH)NRR, OR; R₃
 is CONRR, CO₂R, when R is independently H, substituted alkyl, aryl,
 heteroaryl, in which the vancosamine residue is substituted on the
 vancosamine nitrogen with aryl substituents such as
 dichlorobenzyloxybenzyl, on the C6 position with a polar substituent such
 as amino or substituted amino, and provided with functionality at the
 carboxyl such as amido derivs., have improved activity against bacterial
 infection. Thus, I (R₁ = 3,4-dichlorobenzyloxybenzyl, R₂ = NH₂, R₃ =
 hydroxyethoxyethylamido) was prepd. and tested in vitro for its
 antibacterial activity (MIC = 0.5 to .gtoreq. 500 .mu.g/mL).
 IT 370564-25-3P 370568-71-1P 370568-77-7P
 370568-78-8P 370568-79-9P 370568-80-2P

370568-82-4P 370568-83-5P 370568-84-6P
 370568-85-7P 370568-86-8P 370568-88-0P
 370568-89-1P 370568-90-4P 370568-91-5P
 370568-92-6P 370568-97-1P 370568-98-2P
 370569-02-1P 370569-06-5P 370569-07-6P
 370569-08-7P 370569-10-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of glycopeptide vancomycin analogs as antibacterial agents)

IT 256350-27-3P 308366-56-5P 308367-46-6P
 308367-48-8P 370568-70-0P 370568-72-2P
 370568-73-3P 370568-74-4P 370568-75-5P
 370568-76-6P 370568-81-3P 370568-87-9P
 370568-93-7P 370568-94-8P 370568-95-9P
 370568-96-0P 370568-99-3P 370569-00-9P
 370569-01-0P 370569-05-4P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of glycopeptide vancomycin analogs as antibacterial agents)

IT 256350-62-6 370569-03-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of glycopeptide vancomycin analogs as antibacterial agents)

L12 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:798248 HCAPLUS

DOCUMENT NUMBER: 135:331681

TITLE: Preparation of glycopeptide vancomycin analogs as antibacterial agents

INVENTOR(S): Kahne, Daniel; Walker, Suzanne

PATENT ASSIGNEE(S): Trustees of Princeton University, USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081372	A2	20011101	WO 2001-US11040	20010405
WO 2001081372	A3	20020516		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002042365 A1 20020411 US 2001-818787 20010328

PRIORITY APPLN. INFO.: US 2000-199382P P 20000425

US 2001-818787 A 20010328

OTHER SOURCE(S): MARPAT 135:331681

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Antibacterial glycopeptide vancomycin analogs I bearing optional modifications to the C6 position of the glucose residue attached to the amino acid four of the vancomycin heptapeptide chain, wherein X is O, S, substituted amine; R is H, substituted alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl, aminoalkyl; R1 and R2 are independently substituted alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-carbonyl, heterocyclic-alkyl-carbonyl, alkylsulfonyl, arylsulfonyl; substituted alkyl, acyl, CHO; Z is N3, functionalized O, N, S atoms; are disclosed. Methods of making the compds. and methods of using the compds. to treat a bacterial infection in a host are also disclosed. Thus, I [X = NH, Z = OH, R = CH₂CH₂CH₂CH₂NH₂, R1 = H, R2 = 4-[(3,4-dichlorophenyl)methoxy]benzyl] was prepd. and tested in vitro for their antibacterial activity (MIC = 0.25-6.25 .mu.g/mL).
- IT 370564-24-2P 370564-26-4P 370564-29-7P
370564-30-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of glycopeptide vancomycin analogs as antibacterial agents)
- IT 370564-25-3P 370564-27-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of glycopeptide vancomycin analogs as antibacterial agents)
- IT 370564-33-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of glycopeptide vancomycin analogs as antibacterial agents)
- IT 256349-88-9P 256350-16-0P 256350-17-1P
256350-66-0P 370564-22-0P 370564-23-1P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of glycopeptide vancomycin analogs as antibacterial agents)

L12 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:844506 HCAPLUS
DOCUMENT NUMBER: 134:144404
TITLE: The role of hydrophobic substituents in the biological activity of glycopeptide antibiotics
AUTHOR(S): Kerns, Robert; Dong, Steven D.; Fukuzawa, Seketsu; Carbeck, Jeffrey; Kohler, Joyce; Silver, Lynn; Kahne, Daniel
CORPORATE SOURCE: Departments of Chemistry and Chemical Engineering, Princeton University, Princeton, NJ, 08544, USA
SOURCE: Journal of the American Chemical Society (2000), 122(50), 12608-12609
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Vancomycin and teicoplanin are the two glycopeptide antibiotics that are used clin. Bacteria become resistant to vancomycin and teicoplanin by producing cell wall precursors terminating in d-Ala-d-Lac, a depsipeptide ligand that interacts only weakly with peptide binding pockets of the drugs. The emergence of such antibiotic resistance poses a serious threat to human health. However, it is possible to overcome resistance by attaching a hydrophobic substituent to vancosamine nitrogen of vancomycin. The authors report the synthesis and evaluation of a new class of

vancomycin derivs contg. hydrophobic substituents on the glucose C6 position. The position of hydrophobic substituent influences the mechanism of action. The authors uncovered differences in the mechanism of action of hydrophobically substituted glycopeptide derivs by comparing the biol activities of pares of compds. contg. intact and damaged peptide binding pockets. These compds. have an addnl. biol activity that cannot simply be due to membrane localization. Identifying the source of this activity should lead to a more rational approach to the design of vancomycin derivs that overcome resistance.

IT 256350-01-3P 256350-03-5P 322012-74-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(role of hydrophobic substituents in biol. activity of glycopeptide antibiotics)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:824286 HCAPLUS

DOCUMENT NUMBER: 134:5162

TITLE: Preparation of glycopeptides as antibacterial agents

INVENTOR(S): Kim, Ronald M.; Kahne, Daniel E.; Chapman, Kevin T.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Princeton University

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069893	A1	20001123	WO 2000-US13751	20000519

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6498238	B1	20021224	US 2000-574225	20000519
------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 1999-134841P P 19990519

OTHER SOURCE(S): MARPAT 134:5162

GI



AB Glycopeptides I [R is a polar substituent; K-Ar1-Z-Ar2 is a lipid-like substituent where Ar1 and Ar2 are arom. or heterocyclic groups, each optionally substituted with R1 [R1 = halo, R2, CN, NO2, CF3, fluoromethoxy, NHSO2R2, OR2, SR2, NR22, N+R23, C(O)NR22, SO2NR22, heterocyclyl, CO2R2, C(O)R2, OC(O)R2, NR2C(O)R2, or NHC(O)R2; R2 = H, aryl, alkyl, arylalkyl, (heterocyclyl)alkyl, aroyl, alkanoyl, alkanoyloxy, alkanoylamino, alkylsulfonyl, arylsulfonyl; two R2 groups may form one or more arom. or heterocyclic rings]; K and Z are carbonyl, sulfonyl, alkylene, alkyleneoxy, oxyalkylene, alkyleneamino, aminoalkylene, alkyleneoxyalkylene, alkyleneethio, thioalkylene, alkyleneaminocarbonyl, aminocarbonyl or carbonylamino, alkyleneaminocarbonyl, aminocarbonylalkylene, O, O2C, CO2, alkylene, alkyleneoxycarbonyl, oxycarbonylalkylene, aminosulfonyl or sulfonylamino; Z is not a single bond] were prepd. as antibacterial agents. Thus, N-[4-(3,4-dichlorobenzoyloxy)benzyl]-N-glucose-C6-amino-vancomycin, prepd. from vancomycin hydrochloride by a multistep sequence involving condensation with 4-(3,4-dichlorobenzoyloxy)benzaldehyde, showed MIC = 0.125 .mu.g/mL against *Staphylococcus aureus* Septicemia (in vivo).

IT 256350-68-2P 308366-45-2P 308366-46-3P
 308366-47-4P 308366-48-5P 308366-49-6P
 308366-50-9P 308366-51-0P 308366-52-1P
 308366-53-2P 308366-54-3P 308366-55-4P
 308366-56-5P 308366-57-6P 308366-58-7P
 308366-59-8P 308366-60-1P 308366-61-2P
 308366-62-3P 308366-63-4P 308366-64-5P
 308366-65-6P 308366-66-7P 308366-67-8P
 308366-68-9P 308366-69-0P 308366-70-3P
 308366-71-4P 308366-72-5P 308366-73-6P
 308366-74-7P 308366-75-8P 308366-76-9P
 308366-77-0P 308366-78-1P 308366-79-2P
 308366-80-5P 308366-81-6P 308366-82-7P
 308366-83-8P 308366-84-9P 308366-85-0P
 308366-86-1P 308366-87-2P 308366-88-3P
 308366-89-4P 308366-90-7P 308366-91-8P
 308366-92-9P 308366-93-0P 308366-94-1P

308366-95-2P 308366-96-3P 308366-97-4P
 308366-98-5P 308366-99-6P 308367-00-2P
 308367-01-3P 308367-02-4P 308367-03-5P
 308367-04-6P 308367-05-7P 308367-06-8P
 308367-07-9P 308367-08-0P 308367-09-1P
 308367-10-4P 308367-11-5P 308367-12-6P
 308367-13-7P 308367-14-8P 308367-15-9P
 308367-16-0P 308367-17-1P 308367-18-2P
 308367-19-3P 308367-20-6P 308367-21-7P
 308367-22-8P 308367-23-9P 308367-24-0P
 308367-25-1P 308367-26-2P 308367-27-3P
 308367-28-4P 308367-29-5P 308367-30-8P
 308367-31-9P 308367-33-1P 308367-34-2P
 308367-35-3P 308367-36-4P 308367-37-5P
 308367-38-6P 308367-39-7P 308367-40-0P
 308367-41-1P 308367-42-2P 308367-43-3P
 308367-44-4P 308367-45-5P 308797-97-9P
 308797-98-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of vancomycin analogs as antibacterial agents)

IT 256349-88-9P 256350-62-6P 256351-48-1P
 308367-47-7P 308367-48-8P 308367-49-9P
 308367-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of vancomycin analogs as antibacterial agents)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:725485 HCAPLUS

DOCUMENT NUMBER: 133:296658

TITLE: Preparation of desleucyl glycopeptide antibiotics

INVENTOR(S): Kahne, Daniel; Walker, Suzanne; Silva, Domingos J.

PATENT ASSIGNEE(S): The Trustees of Princeton University, USA; Incara Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 150 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059528	A1	20001012	WO 2000-US8559	20000331
W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1173193	A1	20020123	EP 2000-919942	20000331
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
US 6518243	B1	20030211	US 2000-540761	20000331
PRIORITY APPLN. INFO.:			US 1999-127516P	P 19990402
			WO 2000-US8559	W 20000331

AB Compds. that are analogs of glycopeptide antibiotics are disclosed. The compds. have the formula A1-A2-A3-A4-A5-A6-A7, where each of the groups A2 to A7 is a modified or unmodified .alpha.-amino acid residue, A1 is optional and, when present, is an org. group other than N-substituted leucine, and at least one of the groups A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, where at least one of said sugar residues is modified to bear at least one hydrophobic substituent. Methods of making these compds., compns. including these compds., and methods of using the compds. to treat infections in a host are also disclosed. Antibacterial test data are tabulated for > 350 compds. of the invention.

IT 256350-62-6P 256350-68-2P 256351-39-0P
300583-15-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of desleucyl glycopeptide antibiotics)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:493569 HCAPLUS

DOCUMENT NUMBER: 133:105257

TITLE: Preparation of substituted alpha-linked disaccharides as antibacterial agents

INVENTOR(S): Kahne, Daniel

PATENT ASSIGNEE(S): Princeton University, USA

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042067	A1	20000720	WO 2000-US651	20000112
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1147129	A1	20011024	EP 2000-904285	20000112
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1999-115596P P 19990112
WO 2000-US651 W 20000112

OTHER SOURCE(S): MARPAT 133:105257

GI



AB A compd. which comprises: (i) a saccharide compd. having transglycosylase inhibitory activity; and (ii) a second compd. that is capable of binding a protein or enzyme involved in cell wall biosynthesis, a precursor used in cell wall biosynthesis, the cell wall surface, or combinations thereof. The saccharide compd. is linked directly or through a difunctional linker, to the non-saccharide compd.; provided that: when the non-saccharide compd. is a hexapeptide or a heptapeptide and the saccharide compd. does not contain a phosphate or phosphonate ester, then the saccharide compd. is not linked directly to the non-saccharide compd. through a glycosidic linkage. The non-saccharide compd. includes both "natural" (aglycons that are typically assocd. with a carbohydrate moiety) and "unnatural" (substances that are not typically assocd. with carbohydrate moiety) aglycons. Unnatural aglycons can be selected, for example, from peptide-binding dyes. Disaccharides I wherein R2Y2Y1 is bonded to a ring carbon atom adjacent to the alpha glycosidic linkage; R1 and R3 are independently hydrogen, alkyl, aryl, aralkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-alkyl, heterocyclic-carbonyl or heterocyclic-alkyl-carbonyl; R2 is hydrogen, alkyl, aryl, aralkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, alkanoyl, aroyl, aralkanoyl, heterocyclic, heterocyclic-alkyl, heterocyclic-carbonyl, heterocyclic-alkyl-carbonyl or a peptide comprising 2-6 amino acid residues; R4-R7 are independently hydrogen, or a hydroxyl, amino or thiol protecting group; W1-W4 are independently O, NH or S; R8 is hydrogen, hydroxyl or a hydroxyl protecting group; k, m, n, p and r are independently 0 or 1; X1 is a single bond, O, NR9 or S; X2 is O, NR12, S, C(O)O, C(O)S, C(S)O, C(S)S, C(NR12)O or C(O)NR12; Y1 is a single bond, O, NR10 or S; Y2 is O, NR13, S, C(O)O, C(O)S, C(S)O, C(S)S, C(NR13)O or C(O)NR13; Z1 is a single bond, O, NR11 or S; Z2 is O, NR14, S, C(O)O, C(O)S, C(S)O, C(S)S, C(NR14)O or C(O)NR14; R9-R14 are independently hydrogen, alkyl or aralkyl; none of the pairs X1 and X2, Y1 and Y2, and Z1 and Z2 comprises O and O, S and O, or O and S, resp. A method of treating bacterial infections with the compd. Thus, disaccharide II (Ar = 2,6-dimethoxyphenoxy, Ar1 = chlorobiphenyl) was prepd. and tested in vitro for its antibacterial activity and selectively inhibited peptidoglycan and RNA synthesis.

IT 256349-90-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of substituted alpha-linked disaccharides as antibacterial agents and inhibitors of peptidoglycan and RNA synthesis)

IT 256351-35-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of substituted alpha-linked disaccharides as antibacterial agents and inhibitors of peptidoglycan and RNA synthesis)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:68479 HCAPLUS

DOCUMENT NUMBER: 132:122934

TITLE: Preparation of glycopeptide antibiotics and their combinatorial libraries

INVENTOR(S): Kahne, Daniel; Kerns, Robert; Fukuzawa, Seketsu; Ge, Min; Thompson, Christopher

PATENT ASSIGNEE(S): Princeton University, USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004044	A1	20000127	WO 1999-US15845	19990714
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337103	AA	20000127	CA 1999-2337103	19990714
AU 9949916	A1	20000207	AU 1999-49916	19990714
EP 1095058	A1	20010502	EP 1999-933979	19990714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002520422	T2	20020709	JP 2000-560150	19990714
WO 2000069892	A1	20001123	WO 2000-US13679	20000519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1179011	A1	20020213	EP 2000-936050	20000519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			US 1998-150690P	P 19980714
			US 1999-134839P	P 19990519
			WO 1999-US15845	W 19990714
			WO 2000-US13679	W 20000519

OTHER SOURCE(S): CASREACT 132:122934

AB Glycopeptides A1-A2-A3-A4-A5-A6-A7 [A1 comprises a modified or unmodified .alpha.-amino acid residue, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heterocyclylcarbonyl, heterocyclylalkyl, heterocyclylalkylcarbonyl, alkylsulfonyl, arylsulfonyl, guanidinyll, carbamoyl, or xanthyl; each of A2 to A7 comprises a modified or unmodified .alpha.-amino acid residue, where (i) A1 is linked to an amino group on A2, (ii) each of A2, A4 and A6 bears an arom. side chain which is cross-linked by two or more covalent bonds, and (iii) A7 bears a terminal carboxyl, ester, amide, or N-substituted amide group; one or more of A1 to A7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, at least one of the sugar residues

bearing one or more substituents of the formula YXR, N+R1:CR2R3, N:PR1R2R3, N+R1R2R3 or P+R1R2R3 in which Y is a single bond, O, NR1 or S; X is O, NR1, S, SO2, C(O)O, C(O)S, C(S)O, C(S)S, C(NR1)O, C(O)NR1, or halo (in which case Y and R are absent); R, R1, R2, and R3 are H, alkyl, aryl, aralkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heterocyclylcarbonyl, heterocyclylalkyl, heterocyclylalkylcarbonyl, alkylsulfonyl, or arylsulfonyl] and their pharmaceutically acceptable salts or a chem. library comprising a plurality of the glycopeptides of the invention were prepd. for use as antibiotics. Thus, glucose-C6 modified vancomycin derivs. were prepd. and assayed for antimicrobial activity (min. inhibitory concns. are tabulated).

IT 256350-01-3P 256350-02-4P 256350-03-5P
 256350-04-6P 256350-05-7P 256350-06-8P
 256350-07-9P 256350-08-0P 256350-09-1P
 256350-10-4P 256350-12-6P 256350-15-9P
 256350-16-0P 256350-18-2P 256350-22-8P
 256350-24-0P 256350-26-2P 256350-27-3P
 256350-30-8P 256350-31-9P 256350-32-0P
 256350-33-1P 256350-34-2P 256350-35-3P
 256350-36-4P 256350-39-7P 256350-41-1P
 256350-43-3P 256350-45-5P 256350-47-7P
 256350-49-9P 256350-57-9P 256350-59-1P
 256350-61-5P 256350-62-6P 256350-63-7P
 256350-64-8P 256350-65-9P 256350-67-1P
 256350-69-3P 256350-71-7P 256350-73-9P
 256350-75-1P 256350-79-5P 256350-81-9P
 256350-83-1P 256350-85-3P 256350-89-7P
 256350-91-1P 256350-93-3P 256351-39-0P
 256351-49-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of glycopeptide antibiotics and their combinatorial libraries)

IT 256350-17-1P 256350-21-7P 256350-25-1P
 256350-50-2P 256350-68-2P 256350-74-0P
 256350-84-2P 256350-86-4P 256350-88-6P
 256350-90-0P 256351-37-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of glycopeptide antibiotics and their combinatorial libraries)

IT 256351-06-1 256351-08-3 256351-40-3
 256351-41-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of glycopeptide antibiotics and their combinatorial libraries)

IT 256349-88-9P 256349-89-0P 256349-90-3P
 256349-91-4P 256349-92-5P 256349-93-6P
 256349-94-7P 256349-95-8P 256349-96-9P
 256349-97-0P 256349-98-1P 256349-99-2P
 256350-00-2P 256350-20-6P 256350-28-4P
 256350-29-5P 256350-37-5P 256350-51-3P
 256350-53-5P 256350-55-7P 256350-77-3P
 256350-87-5P 256350-95-5P 256350-96-6P
 256350-97-7P 256350-98-8P 256350-99-9P
 256351-00-5P 256351-01-6P 256351-02-7P
 256351-03-8P 256351-04-9P 256351-09-4P
 256351-10-7P 256351-11-8P 256351-12-9P
 256351-13-0P 256351-16-3P 256351-17-4P
 256351-35-6P 256351-36-7P 256351-38-9P
 256351-45-8P 256351-46-9P 256351-48-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of glycopeptide antibiotics and their combinatorial libraries)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=>

=> fil caold
FILE 'CAOLD' ENTERED AT 18:11:46 ON 18 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>
=>

=> s l11
L13 0 L11

=>
=>

=> fil reg
FILE 'REGISTRY' ENTERED AT 18:11:58 ON 18 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUN 2003 HIGHEST RN 532924-24-6
DICTIONARY FILE UPDATES: 17 JUN 2003 HIGHEST RN 532924-24-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
=>

=> d reg l11 tot

1	RN	474433-10-8	REGISTRY
2	RN	474433-09-5	REGISTRY
3	RN	474433-08-4	REGISTRY
4	RN	474433-07-3	REGISTRY
5	RN	474433-06-2	REGISTRY
6	RN	474433-05-1	REGISTRY
7	RN	474433-04-0	REGISTRY
8	RN	474433-03-9	REGISTRY
9	RN	474433-02-8	REGISTRY
10	RN	474433-01-7	REGISTRY
11	RN	474433-00-6	REGISTRY
12	RN	474432-99-0	REGISTRY
13	RN	474432-98-9	REGISTRY
14	RN	474432-97-8	REGISTRY
15	RN	370569-10-1	REGISTRY
16	RN	370569-08-7	REGISTRY
17	RN	370569-07-6	REGISTRY
18	RN	370569-06-5	REGISTRY
19	RN	370569-05-4	REGISTRY
20	RN	370569-04-3	REGISTRY
21	RN	370569-03-2	REGISTRY
22	RN	370569-02-1	REGISTRY
23	RN	370569-01-0	REGISTRY
24	RN	370569-00-9	REGISTRY
25	RN	370568-99-3	REGISTRY
26	RN	370568-98-2	REGISTRY
27	RN	370568-97-1	REGISTRY
28	RN	370568-96-0	REGISTRY
29	RN	370568-95-9	REGISTRY
30	RN	370568-94-8	REGISTRY
31	RN	370568-93-7	REGISTRY
32	RN	370568-92-6	REGISTRY
33	RN	370568-91-5	REGISTRY
34	RN	370568-90-4	REGISTRY
35	RN	370568-89-1	REGISTRY
36	RN	370568-88-0	REGISTRY
37	RN	370568-87-9	REGISTRY
38	RN	370568-86-8	REGISTRY
39	RN	370568-85-7	REGISTRY
40	RN	370568-84-6	REGISTRY
41	RN	370568-83-5	REGISTRY
42	RN	370568-82-4	REGISTRY
43	RN	370568-81-3	REGISTRY
44	RN	370568-80-2	REGISTRY
45	RN	370568-79-9	REGISTRY
46	RN	370568-78-8	REGISTRY
47	RN	370568-77-7	REGISTRY
48	RN	370568-76-6	REGISTRY
49	RN	370568-75-5	REGISTRY
50	RN	370568-74-4	REGISTRY
51	RN	370568-73-3	REGISTRY
52	RN	370568-72-2	REGISTRY
53	RN	370568-71-1	REGISTRY
54	RN	370568-70-0	REGISTRY
55	RN	370564-33-3	REGISTRY
56	RN	370564-30-0	REGISTRY
57	RN	370564-29-7	REGISTRY
58	RN	370564-27-5	REGISTRY
59	RN	370564-26-4	REGISTRY
60	RN	370564-25-3	REGISTRY
61	RN	370564-24-2	REGISTRY

62	RN	370564-23-1	REGISTRY
63	RN	370564-22-0	REGISTRY
64	RN	322012-74-8	REGISTRY
65	RN	308797-98-0	REGISTRY
66	RN	308797-97-9	REGISTRY
67	RN	308367-50-2	REGISTRY
68	RN	308367-49-9	REGISTRY
69	RN	308367-48-8	REGISTRY
70	RN	308367-47-7	REGISTRY
71	RN	308367-46-6	REGISTRY
72	RN	308367-45-5	REGISTRY
73	RN	308367-44-4	REGISTRY
74	RN	308367-43-3	REGISTRY
75	RN	308367-42-2	REGISTRY
76	RN	308367-41-1	REGISTRY
77	RN	308367-40-0	REGISTRY
78	RN	308367-39-7	REGISTRY
79	RN	308367-38-6	REGISTRY
80	RN	308367-37-5	REGISTRY
81	RN	308367-36-4	REGISTRY
82	RN	308367-35-3	REGISTRY
83	RN	308367-34-2	REGISTRY
84	RN	308367-33-1	REGISTRY
85	RN	308367-31-9	REGISTRY
86	RN	308367-30-8	REGISTRY
87	RN	308367-29-5	REGISTRY
88	RN	308367-28-4	REGISTRY
89	RN	308367-27-3	REGISTRY
90	RN	308367-26-2	REGISTRY
91	RN	308367-25-1	REGISTRY
92	RN	308367-24-0	REGISTRY
93	RN	308367-23-9	REGISTRY
94	RN	308367-22-8	REGISTRY
95	RN	308367-21-7	REGISTRY
96	RN	308367-20-6	REGISTRY
97	RN	308367-19-3	REGISTRY
98	RN	308367-18-2	REGISTRY
99	RN	308367-17-1	REGISTRY
100	RN	308367-16-0	REGISTRY
101	RN	308367-15-9	REGISTRY
102	RN	308367-14-8	REGISTRY
103	RN	308367-13-7	REGISTRY
104	RN	308367-12-6	REGISTRY
105	RN	308367-11-5	REGISTRY
106	RN	308367-10-4	REGISTRY
107	RN	308367-09-1	REGISTRY
108	RN	308367-08-0	REGISTRY
109	RN	308367-07-9	REGISTRY
110	RN	308367-06-8	REGISTRY
111	RN	308367-05-7	REGISTRY
112	RN	308367-04-6	REGISTRY
113	RN	308367-03-5	REGISTRY
114	RN	308367-02-4	REGISTRY
115	RN	308367-01-3	REGISTRY
116	RN	308367-00-2	REGISTRY
117	RN	308366-99-6	REGISTRY
118	RN	308366-98-5	REGISTRY
119	RN	308366-97-4	REGISTRY
120	RN	308366-96-3	REGISTRY
121	RN	308366-95-2	REGISTRY
122	RN	308366-94-1	REGISTRY
123	RN	308366-93-0	REGISTRY
124	RN	308366-92-9	REGISTRY

125	RN	308366-91-8	REGISTRY
126	RN	308366-90-7	REGISTRY
127	RN	308366-89-4	REGISTRY
128	RN	308366-88-3	REGISTRY
129	RN	308366-87-2	REGISTRY
130	RN	308366-86-1	REGISTRY
131	RN	308366-85-0	REGISTRY
132	RN	308366-84-9	REGISTRY
133	RN	308366-83-8	REGISTRY
134	RN	308366-82-7	REGISTRY
135	RN	308366-81-6	REGISTRY
136	RN	308366-80-5	REGISTRY
137	RN	308366-79-2	REGISTRY
138	RN	308366-78-1	REGISTRY
139	RN	308366-77-0	REGISTRY
140	RN	308366-76-9	REGISTRY
141	RN	308366-75-8	REGISTRY
142	RN	308366-74-7	REGISTRY
143	RN	308366-73-6	REGISTRY
144	RN	308366-72-5	REGISTRY
145	RN	308366-71-4	REGISTRY
146	RN	308366-70-3	REGISTRY
147	RN	308366-69-0	REGISTRY
148	RN	308366-68-9	REGISTRY
149	RN	308366-67-8	REGISTRY
150	RN	308366-66-7	REGISTRY
151	RN	308366-65-6	REGISTRY
152	RN	308366-64-5	REGISTRY
153	RN	308366-63-4	REGISTRY
154	RN	308366-62-3	REGISTRY
155	RN	308366-61-2	REGISTRY
156	RN	308366-60-1	REGISTRY
157	RN	308366-59-8	REGISTRY
158	RN	308366-58-7	REGISTRY
159	RN	308366-57-6	REGISTRY
160	RN	308366-56-5	REGISTRY
161	RN	308366-55-4	REGISTRY
162	RN	308366-54-3	REGISTRY
163	RN	308366-53-2	REGISTRY
164	RN	308366-52-1	REGISTRY
165	RN	308366-51-0	REGISTRY
166	RN	308366-50-9	REGISTRY
167	RN	308366-49-6	REGISTRY
168	RN	308366-48-5	REGISTRY
169	RN	308366-47-4	REGISTRY
170	RN	308366-46-3	REGISTRY
171	RN	308366-45-2	REGISTRY
172	RN	300583-15-7	REGISTRY
173	RN	256351-49-2	REGISTRY
174	RN	256351-48-1	REGISTRY
175	RN	256351-46-9	REGISTRY
176	RN	256351-45-8	REGISTRY
177	RN	256351-44-7	REGISTRY
178	RN	256351-41-4	REGISTRY
179	RN	256351-40-3	REGISTRY
180	RN	256351-39-0	REGISTRY
181	RN	256351-38-9	REGISTRY
182	RN	256351-37-8	REGISTRY
183	RN	256351-36-7	REGISTRY
184	RN	256351-35-6	REGISTRY
185	RN	256351-17-4	REGISTRY
186	RN	256351-16-3	REGISTRY
187	RN	256351-13-0	REGISTRY

188	RN	256351-12-9	REGISTRY
189	RN	256351-11-8	REGISTRY
190	RN	256351-10-7	REGISTRY
191	RN	256351-09-4	REGISTRY
192	RN	256351-08-3	REGISTRY
193	RN	256351-06-1	REGISTRY
194	RN	256351-04-9	REGISTRY
195	RN	256351-03-8	REGISTRY
196	RN	256351-02-7	REGISTRY
197	RN	256351-01-6	REGISTRY
198	RN	256351-00-5	REGISTRY
199	RN	256350-99-9	REGISTRY
200	RN	256350-98-8	REGISTRY
201	RN	256350-97-7	REGISTRY
202	RN	256350-96-6	REGISTRY
203	RN	256350-95-5	REGISTRY
204	RN	256350-93-3	REGISTRY
205	RN	256350-92-2	REGISTRY
206	RN	256350-91-1	REGISTRY
207	RN	256350-90-0	REGISTRY
208	RN	256350-89-7	REGISTRY
209	RN	256350-88-6	REGISTRY
210	RN	256350-87-5	REGISTRY
211	RN	256350-86-4	REGISTRY
212	RN	256350-85-3	REGISTRY
213	RN	256350-84-2	REGISTRY
214	RN	256350-83-1	REGISTRY
215	RN	256350-82-0	REGISTRY
216	RN	256350-81-9	REGISTRY
217	RN	256350-80-8	REGISTRY
218	RN	256350-79-5	REGISTRY
219	RN	256350-78-4	REGISTRY
220	RN	256350-77-3	REGISTRY
221	RN	256350-76-2	REGISTRY
222	RN	256350-75-1	REGISTRY
223	RN	256350-74-0	REGISTRY
224	RN	256350-73-9	REGISTRY
225	RN	256350-72-8	REGISTRY
226	RN	256350-71-7	REGISTRY
227	RN	256350-70-6	REGISTRY
228	RN	256350-69-3	REGISTRY
229	RN	256350-68-2	REGISTRY
230	RN	256350-67-1	REGISTRY
231	RN	256350-66-0	REGISTRY
232	RN	256350-65-9	REGISTRY
233	RN	256350-64-8	REGISTRY
234	RN	256350-63-7	REGISTRY
235	RN	256350-62-6	REGISTRY
236	RN	256350-61-5	REGISTRY
237	RN	256350-60-4	REGISTRY
238	RN	256350-59-1	REGISTRY
239	RN	256350-58-0	REGISTRY
240	RN	256350-57-9	REGISTRY
241	RN	256350-56-8	REGISTRY
242	RN	256350-55-7	REGISTRY
243	RN	256350-54-6	REGISTRY
244	RN	256350-53-5	REGISTRY
245	RN	256350-52-4	REGISTRY
246	RN	256350-51-3	REGISTRY
247	RN	256350-50-2	REGISTRY
248	RN	256350-49-9	REGISTRY
249	RN	256350-48-8	REGISTRY
250	RN	256350-47-7	REGISTRY

251	RN	256350-46-6	REGISTRY
252	RN	256350-45-5	REGISTRY
253	RN	256350-44-4	REGISTRY
254	RN	256350-43-3	REGISTRY
255	RN	256350-42-2	REGISTRY
256	RN	256350-41-1	REGISTRY
257	RN	256350-40-0	REGISTRY
258	RN	256350-39-7	REGISTRY
259	RN	256350-38-6	REGISTRY
260	RN	256350-37-5	REGISTRY
261	RN	256350-36-4	REGISTRY
262	RN	256350-35-3	REGISTRY
263	RN	256350-34-2	REGISTRY
264	RN	256350-33-1	REGISTRY
265	RN	256350-32-0	REGISTRY
266	RN	256350-31-9	REGISTRY
267	RN	256350-30-8	REGISTRY
268	RN	256350-29-5	REGISTRY
269	RN	256350-28-4	REGISTRY
270	RN	256350-27-3	REGISTRY
271	RN	256350-26-2	REGISTRY
272	RN	256350-25-1	REGISTRY
273	RN	256350-24-0	REGISTRY
274	RN	256350-23-9	REGISTRY
275	RN	256350-22-8	REGISTRY
276	RN	256350-21-7	REGISTRY
277	RN	256350-20-6	REGISTRY
278	RN	256350-19-3	REGISTRY
279	RN	256350-18-2	REGISTRY
280	RN	256350-17-1	REGISTRY
281	RN	256350-16-0	REGISTRY
282	RN	256350-15-9	REGISTRY
283	RN	256350-14-8	REGISTRY
284	RN	256350-12-6	REGISTRY
285	RN	256350-11-5	REGISTRY
286	RN	256350-10-4	REGISTRY
287	RN	256350-09-1	REGISTRY
288	RN	256350-08-0	REGISTRY
289	RN	256350-07-9	REGISTRY
290	RN	256350-06-8	REGISTRY
291	RN	256350-05-7	REGISTRY
292	RN	256350-04-6	REGISTRY
293	RN	256350-03-5	REGISTRY
294	RN	256350-02-4	REGISTRY
295	RN	256350-01-3	REGISTRY
296	RN	256350-00-2	REGISTRY
297	RN	256349-99-2	REGISTRY
298	RN	256349-98-1	REGISTRY
299	RN	256349-97-0	REGISTRY
300	RN	256349-96-9	REGISTRY
301	RN	256349-95-8	REGISTRY
302	RN	256349-94-7	REGISTRY
303	RN	256349-93-6	REGISTRY
304	RN	256349-92-5	REGISTRY
305	RN	256349-91-4	REGISTRY
306	RN	256349-90-3	REGISTRY
307	RN	256349-89-0	REGISTRY
308	RN	256349-88-9	REGISTRY

=>


=>

=> d ide can 111 1 12 15 25 30 55 64 65 117 172 173 199 297 308


L11 ANSWER 1 OF 308 REGISTRY COPYRIGHT 2003 ACS
RN 474433-10-8 REGISTRY
CN Vancomycin, 6'-deoxy-N3''-[4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]-
6'-(dimethylamino)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C82 H90 Cl4 N10 O24
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:345587


L11 ANSWER 12 OF 308 REGISTRY COPYRIGHT 2003 ACS
RN 474432-99-0 REGISTRY
CN Vancomycin, 6'-deoxy-6'-[[2-(dimethylamino)ethyl]dimethylammonio]-, inner
salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C72 H89 Cl2 N11 O23
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.


PAGE 1-A

OH
0


PAGE 2-A



PAGE 2-B



PAGE 3-A



1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:345587

L11 ANSWER 15 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 370569-10-1 REGISTRY

CN Vancomycin, 6'-amino-26-decarboxy-6'-deoxy-26-[[[5-[[[4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]amino]pentyl]amino]carbonyl]- (9CI)
(CA INDEX NAME)

FS STEREOSEARCH


MF C85 H98 Cl4 N12 O23

SR CA


LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 135:331682

L11 ANSWER 25 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 370568-99-3 REGISTRY

CN Vancomycin, 6'-deoxy-N3'',56-bis[(9H-fluoren-9-ylmethoxy)carbonyl]-6'-iodo-(9CI) (CA INDEX NAME)



FS STEREOSEARCH



MF C96 H94 Cl2 I N9 O27

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.





1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


```
L11 ANSWER 30 OF 308  REGISTRY  COPYRIGHT 2003 ACS
RN 370568-94-8  REGISTRY
CN Vancomycin, 6'-deoxy-N3''-[[4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]-
56-[(9H-fluoren-9-ylmethoxy)carbonyl]-6'-iodo- (9CI)  (CA INDEX NAME)
FS STEREOSEARCH
MF C95 H94 Cl4 I N9 O26
SR CA
LC STN Files:  CA, CAPLUS, USPATFULL
```

Absolute stereochemistry.


PAGE 1-C




PAGE 2-A



PAGE 2-B




PAGE 2-C



PAGE 3-A

Cl



1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 135:331682

L11 ANSWER 55 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 370564-33-3 REGISTRY

CN Vancomycin, 26-[[(4-aminobutyl)amino]carbonyl]-6'-azido-N3'',56-bis[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-26-decarboxy-6'-deoxy- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C96 H102 Cl4 N14 O22

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

H₂N

PAGE 2-B



1 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 135:331681


L11 ANSWER 64 OF 308 REGISTRY COPYRIGHT 2003 ACS
 RN 322012-74-8 REGISTRY
 CN Vancomycin, 6'-[[[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]amino]-49-de[4-methyl-2-(methylamino)-1-oxopentyl]-6'-deoxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C72 H72 Cl3 N9 O22
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.


PAGE 1-A

Me
 :


PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 3-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:180210

REFERENCE 2: 134:144404

L11 ANSWER 65 OF 308 REGISTRY COPYRIGHT 2003 ACS



RN 308797-98-0 REGISTRY

CN Vancomycin, 6'-deoxy-N3''-[[4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]-
6'-[(2-hydroxynaphthalenyl)amino]- (9CI) (CA INDEX NAME)


MF C90 H92 Cl4 N10 O25

CI IDS
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-B



1 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:5162

L11 ANSWER 117 OF 308 REGISTRY COPYRIGHT 2003 ACS
 RN 308366-99-6 REGISTRY
 CN Vancomycin, 6'-deoxy-N3'''-[[4-[(3,4-dichlorophenyl)methoxy]phenyl)methyl]-
 6'-[3-(dimethylamino)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C86 H97 Cl4 N11 O24
 SR CA


LC STN Files: CA, CAPLUS, USPATFULL



Absolute stereochemistry.

PAGE 1-B

OH
□

PAGE 2-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:5162

L11 ANSWER 172 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 300583-15-7 REGISTRY

CN Vancomycin, 6'-amino-49-[(2R)-2-amino-3-(1,1-dimethylethoxy)-1-oxopropyl]-

N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-49-de[4-methyl-2-(methylamino)-1-oxopentyl]-6'-deoxy- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C79 H85 Cl3 N10 O24

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl₁

PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 133:296658

L11 ANSWER 173 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 256351-49-2 REGISTRY

CN Vancomycin, N3''-decyl-6'-deoxy-6'-iodo- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C76 H94 Cl2 I N9 O23

SR CA


LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



NH₂



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:122934


L11 ANSWER 199 OF 308 REGISTRY COPYRIGHT 2003 ACS
RN 256350-99-9 REGISTRY
CN Vancomycin, 26-decarboxy-6'-deoxy-26-[[[2-methoxy-2-oxoethyl)amino]carbonyl]-6'-[[[[[phenylmethoxy)carbonyl]amino][[(phenylmethoxy)carbonyl]imino)methyl]amino]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C86 H95 Cl2 N13 O28
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:122934

L11 ANSWER 297 OF 308 REGISTRY COPYRIGHT 2003 ACS


RN 256349-99-2 REGISTRY

CN Vancomycin, 6'-deoxy-N3'',56-bis[(2-propenyloxy)carbonyl]-6'-[(2-quinoxalinylylcarbonyl)amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)


FS STEREOSEARCH
 MF C86 H92 Cl2 N12 O28
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:122934

L11 ANSWER 308 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 256349-88-9 REGISTRY

CN Vancomycin, N3'',56-bis[(2-propenyloxy)carbonyl]-, 2-propenyl ester, 6'-(2,4,6-trimethylbenzenesulfonate) (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C86 H97 Cl2 N9 O30 S


SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL



Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)

3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 135:331681

REFERENCE 2: 134:5162

REFERENCE 3: 132:122934

=> d ide can 111 1 12 15 25 30 55 64 65 117 172 173 199 297 308

L11 ANSWER 1 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 474433-10-8 REGISTRY

CN Vancomycin, 6'-deoxy-N3'-[[4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]-6'-(dimethylamino)-(9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C82 H90 Cl4 N10 O24

SR CA


LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl

PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:345587

L11 ANSWER 12 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 474432-99-0 REGISTRY

CN Vancomycin, 6'-deoxy-6'-[[2-(dimethylamino)ethyl]dimethylammonio]-, inner salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C72 H89 Cl2 N11 O23

SR CA


LC STN Files: CA, CAPLUS

Absolute stereochemistry.


OH
0



PAGE 2-B



PAGE 3-A




1 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:345587


L11 ANSWER 15 OF 308 REGISTRY COPYRIGHT 2003 ACS
 RN 370569-10-1 REGISTRY
 CN Vancomycin, 6'-amino-26-decarboxy-6'-deoxy-26-[[[5-[[[4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]amino]pentyl]amino]carbonyl]- (9CI)
 (CA INDEX NAME)
 FS STEREOSEARCH
 MF C85 H98 Cl4 N12 O23
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 135:331682

L11 ANSWER 25 OF 308 REGISTRY COPYRIGHT 2003 ACS
RN 370568-99-3 REGISTRY
CN Vancomycin, 6'-deoxy-N3'',56-bis[(9H-fluoren-9-ylmethoxy)carbonyl]-6'-iodo-
(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C96 H94 Cl2 I N9 O27
SR CA
LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.

PAGE 1-A


OH
|




PAGE 2-A



PAGE 2-B



PAGE 3-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 135:331682

L11 ANSWER 30 OF 308 REGISTRY COPYRIGHT 2003 ACS
RN 370568-94-8 REGISTRY
CN Vancomycin, 6'-deoxy-N3'-[4-[(3,4-dichlorophenyl)methoxy]phenyl)methyl]-
56-[(9H-fluoren-9-ylmethoxy)carbonyl]-6'-iodo- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C95 H94 Cl4 I N9 O26
SR CA
LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.



PAGE 2-B




PAGE 2-C



PAGE 3-A

Cl



1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 135:331682

L11 ANSWER 55 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 370564-33-3 REGISTRY

CN Vancomycin, 26-[[[(4-aminobutyl)amino]carbonyl]-6'-azido-N3'',56-bis[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-26-decarboxy-6'-deoxy- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C96 H102 Cl4 N14 O22

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

H₂N

PAGE 2-B



1 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 135:331681


L11 ANSWER 64 OF 308 REGISTRY COPYRIGHT 2003 ACS
 RN 322012-74-8 REGISTRY
 CN Vancomycin, 6'-[[[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]amino]-49-de[4-methyl-2-(methylamino)-1-oxopentyl]-6'-deoxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C72 H72 Cl3 N9 O22
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.


PAGE 1-A

Me


PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 3-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:180210

REFERENCE 2: 134:144404

L11 ANSWER 65 OF 308 REGISTRY COPYRIGHT 2003 ACS



RN 308797-98-0 REGISTRY

CN Vancomycin, 6'-deoxy-N3''-[[4-[(3,4-dichlorophenyl)methoxy]phenyl]methyl]-
6'-[(2-hydroxynaphthalenyl)amino]- (9CI) (CA INDEX NAME)


MF C90 H92 Cl4 N10 O25

CI IDS
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-B

OH

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:5162

L11 ANSWER 117 OF 308 REGISTRY COPYRIGHT 2003 ACS
RN 308366-99-6 REGISTRY
CN Vancomycin, 6'-deoxy-N3''-[4-[(3,4-dichlorophenyl)methoxy]phenyl)methyl]-
6'-[3-(dimethylamino)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C86 H97 Cl4 N11 O24
SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.


PAGE 1-B

OH


PAGE 2-A



PAGE 2-B



PAGE 3-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 134:5162

L11 ANSWER 172 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 300583-15-7 REGISTRY

CN Vancomycin, 6'-amino-49-[(2R)-2-amino-3-(1,1-dimethylethoxy)-1-oxopropyl]-

N3'''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-49-de[4-methyl-2-(methylamino)-1-oxopentyl]-6'-deoxy- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C79 H85 Cl3 N10 O24

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A

Cl..

PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 133:296658

L11 ANSWER 173 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 256351-49-2 REGISTRY

CN	Vancomycin, N3'''-decyl-6'-deoxy-6'-iodo-	(9CI)	(CA INDEX NAME)
----	---	-------	-----------------

FS STEREOSEARCH


MF C76 H94 C12 I N9 O23

SR CA


LC STN Files: CA, CAPLUS, CASREACT


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:122934

L11 ANSWER 199 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 256350-99-9 REGISTRY

CN Vancomycin, 26-decarboxy-6'-deoxy-26-[[(2-methoxy-2-oxoethyl)amino]carbonyl]-6'-[[[(phenylmethoxy)carbonyl]amino][[(phenylmethoxy)carbonyl]imino]methyl]amino]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C86 H95 Cl2 N13 O28

SR CA


LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:122934

L11 ANSWER 297 OF 308 REGISTRY COPYRIGHT 2003 ACS.


RN 256349-99-2 REGISTRY

CN Vancomycin, 6'-deoxy-N3'',56-bis[(2-propenyloxy)carbonyl]-6'-[(2-quinoxalinyloxy)carbonyl]amino]-, 2-propenyl ester (9CI) (CA INDEX NAME)


FS STEREOSEARCH
 MF C86 H92 Cl2 N12 O28
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 132:122934

L11 ANSWER 308 OF 308 REGISTRY COPYRIGHT 2003 ACS

RN 256349-88-9 REGISTRY

CN Vancomycin, N3'',56-bis[(2-propenyloxy)carbonyl]-, 2-propenyl ester, 6'-(2,4,6-trimethylbenzenesulfonate) (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C86 H97 Cl2 N9 O30 S


SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL.



Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 135:331681

REFERENCE 2: 134:5162

REFERENCE 3: 132:122934